Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7611-7620 Newer>

The Motley Fool July 8, 2011	One Biotech Stock to Avoid Our investing community's latest stock to avoid is Zalicus, which in five years has never completed development of any drug or even initiated a phase III trial.
The Motley Fool July 8, 2011 Luke Timmerman	Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies?
Chemistry World July 7, 2011 Elinor Richards	Eight Steps to Foil Antibiotic Resistant Bacteria U.S. scientists have synthesised by a new route a key intermediate for the production of synthetic analogues of natural antibiotic tetracyclines that could be used as potential new drugs to combat the growing ranks of antibiotic resistant bacteria.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
The Motley Fool July 7, 2011	Healthcare Services Group Earnings Preview Healthcare Services Group didn't hit the Street's expectations last quarter, but investors hope that it will rebound when it unveils its latest earnings on Monday, July 11.
The Motley Fool July 7, 2011 Seth Jayson	Why Schiff Nutrition International May Be About to Take Off Although Schiff Nutrition shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon.
The Motley Fool July 6, 2011 Arundhati Parmar	Infuse Furor May Force Medtronic Spine Business Sale. Who Would Buy? Jettisoning the spinal business may not be easy.
The Motley Fool July 5, 2011 Brian Orelli	Drug Approved, But No Fireworks Yet The second FDA approval for Bayer and Johnson & Johnson's Xarelto is more important.
The Motley Fool July 5, 2011 Luke Timmerman	Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Expectations are sky-high.
The Motley Fool July 1, 2011 Dan Radovsky	Can the Human Genetics Industry Survive the Courts? The future of gene patents is at stake.
<Older 7611-7620 Newer> Return to current articles.